<DOC>
	<DOCNO>NCT00951548</DOCNO>
	<brief_summary>This double-blind , randomize , placebo control study ass beneficial effect food supplementation VSL # 3 support standard pharmaceutical therapy patient affect mild moderate active ulcerative colitis .</brief_summary>
	<brief_title>Food Supplementation With VSL # 3 Support Standard Pharmaceutical Therapy Ulcerative Colitis</brief_title>
	<detailed_description>Title : Food supplementation probiotic preparation VSL # 3 support standard pharmaceutical therapy patient mild moderate active Ulcerative Colitis . A double-blind , randomize , placebo control study . Study Design : Double blind , randomise , parallel group , placebo control , multicentre , national study . Study Period : February 2006 - October 2007 ( recruitment : 12 month ; food supplementation VSL # 3 : 8 week ) . Study Population : The study population comprise 144 patient mild moderate active ulcerative colitis top standard pharmaceutical therapy . 72 patient randomise receive food supplementation VSL # 3 72 receive placebo . Total Number center : Approximately 16 Study Objectives : To assess beneficial effect food supplementation VSL # 3 patient affected mild moderate active ulcerative colitis double-blind , placebo-controlled study . Study product : VSL # 3 consists sachet contain 900 billion viable lyophilise bacteria , comprise 4 strain Lactobacillus ( L. paracasei , L. plantarum , L. acidophilus L. delbrueckii subsp . bulgaricus ) , 3 strain Bifidobacterium ( B. longum , B. breve B. infantis ) 1 strain Streptococcus thermophilus , maltose silicon dioxide excipients . The placebo form identical sachet contain maltose silicon dioxide . The dose receive patient two sachet VSL # 3 placebo take twice day orally ( total amount bacteria : 3.600 billion organism per day ) . Assessments : Primary Outcome The primary outcome evaluation beneficial effect food supplementation VSL # 3 patient affected UC , assess decrease UCDAI 50 % , baseline week 8 . Secondary Outcomes : Assessment beneficial effect food supplementation probiotic preparation VSL # 3 : - activity ulcerative colitis . - change subjective symptom ( rectal bleeding stool frequency ) baseline week 2 , 4 8 food supplementation VSL # 3 . - lack beneficial effect , define need food supplementation inability stay study till week 8 . - quality life questionnaire ( IBDQ ) - concordance Physician Patient Global Assessment Scale time point . Physical Status Evaluations : Assessment haematological laboratory test , vital sign ( blood pressure , pulse rate respiratory rate ) , medical history physical examination .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>1 . Male female patient age 18 year ; 2 . Diagnosis ulcerative colitis establish previous colonoscopy , consistent histology clinical course ; 3 . Ulcerative colitis extend 15 cm anal verge , involve least rectosigmoid . This base colonoscopy time since onset ulcerative colitis . Activity ( extent ) must confirm colonoscopy begin study ; 4 . Mild moderate active ulcerative colitis . Patients must minimum score 3 maximum score 8 12 point UCDAI ( Ulcerative Colitis Disease Activity Index see Appendix 3 ) measure stool frequency , rectal bleeding , endoscopic finding physician 's overall assessment disease severity ; 5 . Symptomatic ( current episode ) less 4 week ; 6 . Minimum endoscopic score 2 UCDAI screening ( mucosal appearance ) ; 7 . Use oral 5ASA least 4 week prior study entry , dose ; and/or use Azathioprine 6mercaptopurine least 3 month prior study entry , dose ; 8 . Negative pregnancy test screen agree use valid contraception duration study ; 9 . Patient require hospitalisation ; 10 . Willing able provide write informed consent 1 . Crohn 's disease pouchitis ; 2 . UCDAI great 8 ( need emergency surgery presence severe disease ; 3 . Use oral steroid within last 4 week prior study entry ; 4 . Use antibiotic within last 2 week prior study entry ; 5 . Change dose oral 5ASA within last 4 week prior study entry throughout 8 week study period , change dose oral 6mercaptopurine azathioprine drug within last 3 month prior study entry throughout 8 week study period ; 6 . Use rectal 5ASA steroid one week throughout 8 week study period ; 7 . Use probiotic preparation either prescribed overthecounter within 2 week prior study entry ; 8 . Use NSAIDS one week throughout 8 week study period ; 9 . Significant hepatic , renal , endocrine , respiratory , neurological cardiovascular disease determine Investigator ; 10 . History severe adverse reaction know hypersensitivity maltose and/or silicon dioxide ; 11 . Patient require hospitalisation ; 12 . Pregnant lactate woman , woman child bear potential use acceptable form birth control ( negative pregnancy test also require ) ; 13 . Use investigational drug and/or participation clinical trial within 3 month entry study ; 14 . Inability give valid informed consent properly follow protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Probiotics</keyword>
	<keyword>VSL # 3</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Placebo control</keyword>
</DOC>